Prulifloxacin as a trigger of myasthenia gravis

ARTICLE in JOURNAL OF THE NEUROLOGICAL SCIENCES · MARCH 2009
Impact Factor: 2.47 · DOI: 10.1016/j.jns.2009.01.019 · Source: PubMed

4 CITATIONS

4 READS

4 AUTHORS, INCLUDING:

Riccardo Mazzocchio
Azienda Ospedaliera Universitaria Senese

68 PUBLICATIONS  2,259 CITATIONS

Available from: Riccardo Mazzocchio
Retrieved on: 15 October 2015
Fluoroquinolones has been associated with exacerbation of myasthenia gravis (MG) and are currently contraindicated in patients affected by MG [1]. We describe a patient in whom exposure to prulifloxacin, a new broad-spectrum oral fluoroquinolone, unmasked subclinical MG.

A 77 year-old woman, with an uneventful history, was prescribed prulifloxacin (600 mg/day for 6 days) after an acute episode of cystitis. Two days after the end of treatment, she developed left sided ptosis. She was then admitted to a neurological department. A detailed history excluded previous signs and symptoms suggestive of MG. On the other hand, a brain MRI excluded acute vascular or compressive lesions and a colour Doppler ultrasound of epiaortic vessels did not show functionally relevant stenosis. Thyroid scintigraphy was compatible with thyroiditis, and metimazole was prescribed. Antibodies anti-acetylcholine receptors were found to be positive. No evidence of thymoma was found. EMG was not performed. Therapy with pyridostigmine and prednisone was started with immediate improvement of left sided ptosis. The patient was discharged from hospital 11 days after admission.

Fluoroquinolones have been associated with anecdotal reports of MG. A literature search conducted on PubMed and EMBASE revealed a total of 7 publications for a total of 8 cases (one report described two cases) summarized in Table 1. Exacerbation of previously diagnosed MG has been reported with the use of ciprofloxacin, pefloxacin, ofloxacin, and norfloxacin [2,3,5–7]. In one case ciprofloxacin unmasked subclinical MG that had not been diagnosed [4]. In addition, a severe respiratory crisis was associated to levoxacin administration in a patient subsequently diagnosed of thymoma [8].

Fluoroquinolones contain quinolone moiety, as chloroquine, quinine and quindine. All these drugs may interfere with neuromuscular transmission postsynaptically for their direct effect on AChR ion channel, as shown by a dose-dependent decrease in the amplitude of miniature endplate potentials (MEPPs) [9,10].

On the basis of the current evidence, we postulate an association between the treatment with prulifloxacin and the unmasking of subclinical MG in our case. The present case was reported to the Italian Pharmacovigilance System (registered as number 87438) and to the manufacturer of the drug.

Fluoroquinolones are widely prescribed drugs and neuromuscular side effects are probably very rare. To our knowledge, no case of MG related to a course of prulifloxacin has been reported to date. According to the published literature, fluoroquinolones of any generation should be avoided in patients with MG.

Acknowledgement

We thank Dr. P Barbafiera for reporting the case.

References

Table 1
Reported cases of MG related to fluoroquinolones therapy.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patient age/sex</th>
<th>Drug</th>
<th>Latency</th>
<th>Previous diagnosis</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mumford CJ, 1990 [4]</td>
<td>73/M</td>
<td>Ciprofloxacin</td>
<td>2 days</td>
<td>No</td>
<td>Dysphagia, dysarthria, left ptosis</td>
</tr>
<tr>
<td>Azevedo E, 1993 [5]</td>
<td>25/F</td>
<td>Ofloxacin</td>
<td>2 days</td>
<td>Yes</td>
<td>Ptosis, diplopia, dysphagia, dyspnea, muscle weakness of limbs and neck</td>
</tr>
<tr>
<td>Roquer J, 1996 [7]</td>
<td>76/F</td>
<td>Ciprofloxacin</td>
<td>3 days</td>
<td>Yes</td>
<td>Diplopia, left ptosis; generalized weakness</td>
</tr>
<tr>
<td>Roquer J, 1996 [7]</td>
<td>79/M</td>
<td>Ciprofloxacin</td>
<td>5 days</td>
<td>Yes</td>
<td>Facial weakness, progressive dysphagia</td>
</tr>
<tr>
<td>Gunduz A, 2006 [8]</td>
<td>45/M</td>
<td>Levofloxacin</td>
<td>1 day</td>
<td>12 h</td>
<td>Respiratory insufficiency</td>
</tr>
</tbody>
</table>